Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26131983 | 0.86 | MAPT (0.51) | ALDH1A1MAPK1HTTOPRK1MAPT | |
| SCHEMBL31013246 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1HTTOPRK1CYP1A2 | |
| SCHEMBL29969961 | 0.86 | MAPT (0.51) | ALDH1A1MAPK1HTTOPRK1MAPT | |
| SCHEMBL13999699 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPK1HTTOPRK1CYP1A2 | |
| SCHEMBL3435641 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MAPK1HTTOPRK1CYP1A2 | |
| SCHEMBL29493167 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPK1HTTOPRK1CYP1A2 | |
| SCHEMBL26130393 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPK1HTTOPRK1CYP1A2 | |
| SCHEMBL2711110 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPK1HTTOPRK1CYP1A2 | |
| SCHEMBL29969095 | 0.82 | OPRK1 (0.57) | ALDH1A1MAPK1HTTOPRK1CYP1A2 | |
| SCHEMBL26130650 | 0.82 | OPRK1 (0.57) | ALDH1A1MAPK1HTTOPRK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ALDH1A1 975/4885MAPK1 1316/4885HTT 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.